Skip Page Header

Home > Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006.

European Monitoring Centre for Drugs and Drug Addiction. (2020) Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006. Luxembourg: Publications Office of the European Union.

[img]
Preview
PDF (Isotonitazene) - Published Version
1MB

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020. On the basis of the Risk Assessment Report, on 2 September 2020, the Commission decided that isotonitazene should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA. Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with Commission Delegated Directive (EU) 2020/1687 by 3 June 2021.


Item Type
Report
Publication Type
International, Report
Drug Type
Opioid, New psychoactive substance
Intervention Type
Harm reduction
Date
November 2020
Pages
55 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)
Related URLs

Repository Staff Only: item control page